Patient reported outcome measures for cardiac ablation procedures: a multicentre pilot to develop a new questionnaire

Kathleen L. Withers, Cardiff and Vale University Health Board
Judith White, Cardiff and Vale University Health Board
Grace Carolan-Rees, Cardiff and Vale University Health Board
Hannah Patrick, Natl Inst Hlth & Care Excellence
Peter O'Callaghan, Cardiff and Vale University Health Board
Stephen Murray, Freeman Hospital
David Cunningham, University College London
Kathryn Wood, Emory University
Mauro Lencioni, New Queen Elizabeth Hospital
Michael Griffith, New Queen Elizabeth Hospital

Journal Title: EP-Europace
Volume: Volume 16, Number 11
Publisher: Oxford University Press (OUP): Policy B - Oxford Open Option B | 2014-11-01, Pages 1626-1633
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1093/europace/euu032
Permanent URL: https://pid.emory.edu/ark:/25593/s5v6j

Final published version: http://dx.doi.org/10.1093/europace/euu032

Copyright information:
© 2014 Published on behalf of the European Society of Cardiology. All rights reserved.
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Accessed December 15, 2018 5:26 AM EST
Patient reported outcome measures for cardiac ablation procedures: a multicentre pilot to develop a new questionnaire

Kathleen L. Withers¹*, Judith White¹, Grace Carolan-Rees¹, Hannah Patrick², Peter O’Callaghan³, Stephen Murray⁴, David Cunningham⁵, Kathryn A. Wood⁶, Mauro Lencioni⁷, and Michael Griffith⁷

¹Cedar, Cardiff and Vale University Health Board, Cardiff MediCentre, Heath Park, Cardiff, CF14 4UJ, UK; ²National Institute of Health and Care Excellence, 10 Spring Gardens, London, SW1A 2BU, UK; ³Cardiology Department, Cardiff and Vale University Health Board, Heath Park, Cardiff, CF14 4UJ, UK; ⁴Cardiology Department, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle Upon Tyne, NE7 7DN, UK; ⁵National Institute for Cardiovascular Outcomes Research, University College London Institute of Cardiovascular Outcomes, London, W1T 7HA, UK; ⁶Duke University, Durham, North Carolina, USA; and ⁷Cardiology Department, University Hospitals Birmingham NHS Foundation Trust, New Queen Elizabeth Hospital, Birmingham, B15 2WB, UK

Received 17 October 2013; accepted after revision 27 January 2014; online publish-ahead-of-print 13 March 2014

Aim

To assess the feasibility of administering Patient Reported Outcomes Measures (PROMs) in patients treated with ablation for cardiac arrhythmias, and to conduct the first stage of development and testing of a new PROM tool.

Methods and results

A new tool was developed by a multidisciplinary team and tested alongside an adaptation of the patient perception of arrhythmia questionnaire (PPAQ) and EQ-5D-5L in a multicentre retrospective audit involving 791 consecutive cardiac arrhythmia patients treated with catheter ablation at three UK centres over 13 months. Data were recorded in the National Cardiac Rhythm Management Database, part of the National Institute for Cardiovascular Outcomes Research. The response rate was 71.9% (n = 569). Patients reported significant improvements across all outcomes and impacts, with reductions in symptoms of 51.7% (heart racing), 33.9% (fatigue) 31.8% (heart flutters), 43.5% (dizziness), 38.6% (breathlessness), 44.2% (chest pressure), 33.1% (trouble concentrating), 15.9% (headache), 28.3% (neck pressure), and 23.4% (fainting) (P < 0.001). The mean number of social days affected reduced by 7.49 days/month (P < 0.001); mean work/school days affected/month reduced by 6.26 (P < 0.001); mean GP/hospital visits reduced by 1.36 days/month (P < 0.001). The procedure met patient expectations in 72% of responders.

Conclusions

The high response rate suggests that the use of PROMs in this patient group is feasible, with rates equalling those of the National PROMs Programme. The results showed that patients experienced significant improvements in their quality of life following ablation, while feedback allowed the tools to be improved. Further work is required to validate these tools; however, the findings suggest that PROMs could be useful in the audit of ablation techniques.

Keywords

Patient reported outcome measures • PROMs • Cardiac ablation • Arrhythmia • Quality of life

Introduction

The effectiveness of medical interventions has traditionally been measured from a clinical perspective, looking at factors including complication and mortality rates, with clinical improvements assessed by healthcare staff. However, emphasis is increasingly being placed on gaining patients’ own perceptions of treatment success¹ using methods such as Patient Reported Outcome Measures (PROMs). Patient Reported Outcome Measures are questionnaires which are administered both before and after a procedure or treatment to measure changes in a patient’s opinion of their health status following an intervention. A PROM tool may be generic, such as EQSD,² which assesses general health status and may be used in any population, or disease-specific, assessing the impact of...
What’s new?

- Collecting Patient-Reported Outcomes in patients treated with ablation techniques for cardiac arrhythmias is a feasible way of measuring procedural success.
- The majority of responders were positive about the outcome of their ablation, with over 72% of patients reporting that the procedure had met their expectations.

Methods

Questionnaires

The cardiac ablation PROM tool comprised three individual questionnaires used as a single tool. The first, a short arrhythmia-specific questionnaire, was developed following literature reviews and research, with input from a multidisciplinary team of cardiac consultants, arrhythmia nurses, clinical advisors, and research scientists. This tool explored patients’ treatment expectations prior to the procedure and whether these were subsequently met. It also considered the number of ablations received and investigated unexpected complications arising from the procedure. The second element of the tool comprised of a modification of the arrhythmia-specific PPAQ questionnaire developed by Wood et al. This was originally developed using techniques including formative research, exploratory factor analysis, expert review, and pilot study. Following adaptations for use in a UK population, this updated tool included seven domains covering severity of symptoms, regularity and length of adverse features, impact on social life and normal routine, arrhythmia-related visits to GP/hospital, and impact on life.

The third element was the generic EQ-5D-5L questionnaire, a validated tool consisting of five domains assessing mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain includes five levels of response ranging from no problems to severe problems. It also has a visual analogue scale (VAS) inviting patients to rate their health on a scale of 0–100 with 0 being the worst health imaginable and 100 being the best imaginable. Supporting documentation, including the cover letter and consent form, was also developed, including Welsh translations. A contact name and telephone number were provided for patients’ queries.

Study design

The tools were designed to be completed by patients before the procedure and again at a minimum of eight weeks post-procedure. However, due to time constraints of the pilot, a retrospective study design was used, whereby patients were sent pre- and post-procedure questionnaires at the same time and asked to complete the pre-procedure questionnaires from memory. Reminders containing copies of the documentation were sent out 16–29 days after the first contact to non-responders.

Participants

A cohort of 800 patients who had received radiofrequency ablation therapy for a cardiac arrhythmia prior to the start of the study on 1 November 2010 from three treatment centres were retrospectively identified for inclusion. Participants were required to (i) have received a cardiac ablation a minimum of 8 weeks prior to the study; (ii) be aged ≥17 at the time of the study; and (iii) have had their details entered onto the Central Cardiac Audit Database (CCAD), part of the National Institute for Cardiovascular Outcomes Research. Consecutive patients were enrolled from each site: Queen Elizabeth Hospital, University Hospitals Birmingham (400 patients); The Freeman Hospital, Newcastle Upon Tyne NHS Trust (200 patients), and University Hospital of Wales, Cardiff & Vale University Health Board (200 patients). Three patients from Birmingham and six from Newcastle were subsequently removed from the study as they were determined to be duplicate patients who had moved house or been retreated, or were identified as deceased; this left 791 patients in the study group.

Data collection, storage, and analysis

Responses were sent to Cedar; an NHS organization independent of the treatment clinics, for data entry and logged onto the CCAD with 15% of entries checked for accuracy. The CCAD is a clinical audit facility which collects information on cardiac procedures within the UK. It is used as a confidential data collection point allowing comparative reporting between treatment centres, data quality reporting, and mortality tracking, with all UK ablation centres highly encouraged to submit procedural data. A specially designed extension to the CCAD was developed to allow the linkage of PROMs returns to existing clinical data while retaining patient anonymity. Clinical data and PROMs data were stored separately.
to prevent clinical staff accessing individual identifiable PROM data at any stage.

Data were analysed using SPSS (IBM SPSS Statistics Version 21) and a 5% significance level was used. For statistical analysis, missing values were excluded on a pairwise basis. EQ-5D questionnaires were scored using the EQ-5D-5L Crosswalk index value calculator. Differences between pre- and post-procedure nominal variables (e.g. presence or absence of symptoms) were analysed using McNemar’s test. Differences between pre- and post-procedure means of continuous data were analysed using a paired-sample t-tests, where the appropriateness of parametric tests was in question, a related-sample Wilcoxon signed-rank test was used.

Results

Responses
An initial response rate of between 45% and 50% was achieved from each centre following initial mailing, rising to a rate of 70–75% from each centre after reminders had been sent, with a final total of 569 analysable responses (71.9%). Three responses were received after the study end date and were excluded from analysis. In 12 cases, a narrative response was received without a completed questionnaire with reasons cited for non-completion including death, ill health, and on-going treatment. One letter was returned to the sender.

Fifteen telephone enquiries were received regarding the questionnaires. In five cases, this was to inform the team that patients were unable to complete the questionnaire due to ill health (two patients), death (two patients), and emigration (one patient). One enquiry was received from a patient requiring advice regarding ongoing health and on-going treatment. One letter was returned to the sender.

Every symptom studied showed a reduction in the proportion of patients reporting both severe and moderate symptoms (not combined). Again heart racing showed the largest improvement after treatment (Figure 2) with patients reporting severe and moderate heart racing reducing from 342 (63.7%) and 134 (25.0%) to 43 (8.3%) and 69 (13.3%), respectively. The smallest reduction was reported for headache with severe and moderate headaches reducing from 39 (8.3%) and 69 (13.3%), respectively. The largest difference in symptom prevalence between the pre- and post-procedure reported symptoms was in heart racing [pre-procedure 510 patients (89.6%), post-procedure 225 patients (39.5%)] and the smallest was in headache [pre-procedure 216 patients (38.0%), post-procedure 154 patients (27.1%)]. Table 2 further illustrates changes in patient symptoms within the three largest arrhythmia substrate groups. Within these groups, atrio-ventricular nodal re-entrant tachycardia (AVNRT) patients were most likely to report a complete abolition of symptoms. However, the picture for symptom improvement was more mixed across the substrates, and with the exception of chest pressure, over 50% of patients from each group reported an improvement in symptom severity.

Changes in the impact of symptoms on functional ability
The PROM tool investigated the number of days’ impact on social activities, days missed at work/school/college, and number of GP/hospital visits in the 30 days prior to the procedure and the 30 days prior to receiving the questionnaires post procedure. There was a reduction in the mean score after ablation in all the three impact parameters for the total participant group ($P < 0.001$) and across all 10 substrates (Table 3). For social days affected, statistically significant differences ($P < 0.05$) were observed in 9 of 10 substrates; for both work/school days affected and GP/hospital visits, statistically

Table 1 Patient data by substrate

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Number (%)</th>
<th>Mean age (range)</th>
<th>Male (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atrial flutter—common (c/Flutter)</td>
<td>143 (25.2)</td>
<td>63.1 (26–88)</td>
<td>105 (73.4)</td>
</tr>
<tr>
<td>AF</td>
<td>131 (23.0)</td>
<td>59.6 (28–79)</td>
<td>95 (72.5)</td>
</tr>
<tr>
<td>AVNRT</td>
<td>126 (22.1)</td>
<td>50.1 (18–86)</td>
<td>42 (33.3)</td>
</tr>
<tr>
<td>Complete AVN</td>
<td>42 (7.4)</td>
<td>74.7 (50–88)</td>
<td>18 (42.9)</td>
</tr>
<tr>
<td>Overt accessory pathway (oAP)</td>
<td>34 (6.0)</td>
<td>47.1 (18–81)</td>
<td>14 (41.2)</td>
</tr>
<tr>
<td>Atrial tachycardia (AT)</td>
<td>28 (5.0)</td>
<td>59.6 (17–85)</td>
<td>9 (32.1)</td>
</tr>
<tr>
<td>Ventricular tachycardia (VT)</td>
<td>20 (3.5)</td>
<td>57.2 (22–80)</td>
<td>12 (60.0)</td>
</tr>
<tr>
<td>Atrial flutter—common (c/Flutter)</td>
<td>15 (2.6)</td>
<td>36.4 (17–55)</td>
<td>7 (46.7)</td>
</tr>
<tr>
<td>Ventricular Ectopies (VE)</td>
<td>12 (2.1)</td>
<td>53.2 (26–75)</td>
<td>7 (58.3)</td>
</tr>
<tr>
<td>Total</td>
<td>569 (100)</td>
<td>57.8 (17–88)</td>
<td>315 (55)</td>
</tr>
</tbody>
</table>
significant differences ($P < 0.05$) were observed in 6 of 10 substrates (Table 3). The largest improvements in days affected (either social or work/school) were observed in atrio-ventricular nodal, AVN [a reduction of 8.48 social days affected ($P = 0.002$); 11.90 reduction in work/school days affected ($P = 0.001$)] and VE substrates [a reduction of 9.36 social days affected ($P = 0.011$); a reduction of 10.30 work/school days affected ($P = 0.016$)]; VE also accounted for the highest significant improvement in number of GP/hospital visits (3.36 reduction ($P = 0.026$)).

### EQ5D data

The complete index values for both pre- and post-procedure questionnaires were available for 498 patients; these showed improvements in general health in 349 patients (70.1%). No change was observed in 97 (19.5%) patients, while 52 patients (10.4%) reported a worsening in general health. EQ5D VAS score had paired sample pre- and post-procedure responses for 530 patients. Here, improvements were observed in 399 patients (75.3%), with no change in 85 patients (16.1%) and poorer post-procedure general health.
reported in 46 patients (8.7%). The EQ5D VAS score showed a statistically significant difference pre- and post-procedure (19.09 mean improvement; \( P \leq 0.005 \)); at a substrate level a statistically significant improvement was also seen for all substrates, except ventricular tachycardia (VT, \( P \leq 0.61 \)); AT mean improvement 9.2 \( (P = 0.002) \); AF mean improvement 21.09 \( (P = < 0.005) \); AVN mean improvement 18.31 \( (P \leq 0.005) \); AVNRT mean improvement 17 \( (P \leq 0.005) \); concealed accessory pathway (cAP) mean improvement 19.36 \( (P = 0.001) \); oAP mean improvement 12.5 \( (P = 0.012) \); u/Flutter mean improvement 19.69 \( (P < 0.005) \); c/Flutter mean improvement 27.73 \( (P = 0.003) \).

Unexpected complications

A total of 213 unexpected post-procedural complications were reported by 190 (33.4%) patients. These included clinical complications such as three cases of cardiac tamponade (incidence rate 0.5%), two transient ischaemic attacks (0.4%), and six strokes (1.1%). Excessive bruising was reported by 75 patients (13.2%), while “Other complications” including headache, bleeding at the entry site, tachycardia, chest pain, and dizziness were reported by 79 patients (13.9%), with one femoral pseudoaneurysm reported. Extended or re-hospitalizations for reasons including infections, pneumonia, dyspnoea, pulmonary embolism, and myocardial infarction were reported by 46 patients (8.1%). The majority of responders were positive about the outcome of their ablation, with 413 of 545 patients (75.8%) reporting that the procedure had met their expectations. Analysis of this outcome for the three most prevalent substrate groups revealed that expectations were met in 72.4, 88.6, and 72.8% of AF, AVNRT, and c/Flutter patients, respectively.

Non-responder data

Analysis of non-responder data using CCAD records found that non-responders were significantly more likely to have had a completely successful procedure \( (P < 0.024) \) (acute success assessed by the clinician). This finding is suggestive that the PROMs may underestimate the clinical benefit. The length of time between the procedure and receiving the PROM was also significant \( (P < 0.019) \), with patients who sent the questionnaires at \( < 9 \) months post-procedure more likely to reply than those who sent it at \( \geq 9 \) months. Age was also a significant factor, with non-responders likely to be younger than responders \( (P < 0.001) \). Gender, occurrence of complications, and urgency of treatment (elective vs. emergency) did not show any significant differences in response rates.

Issues and weaknesses

Responses highlighted weaknesses in some areas of the questionnaires. These included a lack of clarity with wording of some questions, e.g. for patients who had undergone a previous procedure “Please state how many you have had” did not specify whether to include the current procedure. Some patients indicated more than one answer for some questions as it was not specified that only one answer should be chosen. The questionnaires also attempted to capture the number of work days (or equivalent) affected by...
### Table 3

| Substrate | n | AT | 95% CI | P value | AF | 95% CI | P value | AVN | 95% CI | P value | AVNRT | 95% CI | P value | cAP | 95% CI | P value | oAP | 95% CI | P value | u/Flutter | 95% CI | P value | c/Flutter | 95% CI | P value | VE | 95% CI | P value | VT | 95% CI | P value | Total | 95% CI | P value |
|-----------|---|-----|--------|---------|---|--------|---------|-----|--------|---------|-------|--------|---------|-----|--------|---------|----|--------|---------|--------|--------|---------|-----|--------|---------|------|--------|---------|-------|
| Social days affected | n | Reduction | 95% CI | P value | n | Reduction | 95% CI | P value | n | Reduction | 95% CI | P value | n | Reduction | 95% CI | P value | n | Reduction | 95% CI | P value | n | Reduction | 95% CI | P value | n | Reduction | 95% CI | P value | n | Reduction | 95% CI | P value | n | Reduction | 95% CI | P value |
| AT | 23 | 7.79 | 2.62–13.30 | 0.003 | 110 | 6.47 | 4.31–8.64 | 0.001 | 103 | 7.79 | 5.57–10.00 | 0.001 | 12 | 7.00 | 5.12 | 3.52–8.49 | 0.001 | 11 | 8.47 | 7.34–9.60 | 0.001 | 117 | 8.19 | 6.99–9.40 | 0.001 | 11 | 9.46 | 7.99–11.00 | 0.001 | 11 | 7.49 | 6.42–8.55 | 0.001 |
| AF | 796 | 7.97 | 2.62–13.30 | 0.003 | 647 | 6.47 | 4.31–8.64 | 0.001 | 579 | 7.79 | 5.57–10.00 | 0.001 | 70 | 7.00 | 5.12 | 3.52–8.49 | 0.001 | 84 | 8.47 | 7.34–9.60 | 0.001 | 957 | 8.19 | 6.99–9.40 | 0.001 | 94 | 9.46 | 7.99–11.00 | 0.001 | 94 | 7.49 | 6.42–8.55 | 0.001 |
| AVN | 29 | 8.48 | 3.48–13.48 | 0.002 | 119 | 6.89 | 5.57–8.21 | 0.001 | 100 | 7.99 | 5.57–10.00 | 0.001 | 11 | 7.00 | 5.12 | 3.52–8.49 | 0.001 | 11 | 8.47 | 7.34–9.60 | 0.001 | 117 | 8.19 | 6.99–9.40 | 0.001 | 11 | 9.46 | 7.99–11.00 | 0.001 | 11 | 7.49 | 6.42–8.55 | 0.001 |
| AVNRT | 103 | 7.79 | 5.57–10.00 | 0.001 | 102 | 7.99 | 5.57–10.00 | 0.001 | 107 | 7.79 | 5.57–10.00 | 0.001 | 12 | 7.00 | 5.12 | 3.52–8.49 | 0.001 | 11 | 8.47 | 7.34–9.60 | 0.001 | 117 | 8.19 | 6.99–9.40 | 0.001 | 11 | 9.46 | 7.99–11.00 | 0.001 | 11 | 7.49 | 6.42–8.55 | 0.001 |
| cAP | 12 | 7.00 | 5.12 | 3.52–8.49 | 0.001 | 11 | 8.47 | 7.34–9.60 | 0.001 | 11 | 9.46 | 7.99–11.00 | 0.001 | 11 | 7.49 | 6.42–8.55 | 0.001 |
| oAP | 26 | 5.12 | 3.52–8.49 | 0.001 | 25 | 3.96 | 1.76–8.19 | 0.065 | 28 | 4.86 | 1.85–11.57 | 0.149 | 12 | 7.00 | 5.12 | 3.52–8.49 | 0.001 | 11 | 8.47 | 7.34–9.60 | 0.001 | 11 | 9.46 | 7.99–11.00 | 0.001 | 11 | 7.49 | 6.42–8.55 | 0.001 |
| u/Flutter | 15 | 7.67 | 1.90–13.44 | 0.013 | 13 | 6.69 | 0.70–12.68 | 0.031 | 14 | 3.07 | 0.92–7.95 | 0.049 | 11 | 7.79 | 5.57–10.00 | 0.001 | 11 | 8.47 | 7.34–9.60 | 0.001 | 11 | 9.46 | 7.99–11.00 | 0.001 | 11 | 7.49 | 6.42–8.55 | 0.001 |
| c/Flutter | 117 | 8.29 | 5.99–10.60 | 0.001 | 111 | 7.15 | 4.86–9.45 | 0.001 | 120 | 1.33 | 0.32–14.32 | 0.059 | 12 | 7.00 | 5.12 | 3.52–8.49 | 0.001 | 11 | 8.47 | 7.34–9.60 | 0.001 | 11 | 9.46 | 7.99–11.00 | 0.001 | 11 | 7.49 | 6.42–8.55 | 0.001 |
| VE | 11 | 9.36 | 2.69–16.04 | 0.011 | 10 | 10.30 | 2.38–18.22 | 0.016 | 11 | 3.36 | 0.49–6.23 | 0.026 | 10 | 9.36 | 2.69–16.04 | 0.011 | 10 | 10.30 | 2.38–18.22 | 0.016 | 11 | 3.36 | 0.49–6.23 | 0.026 | 10 | 9.36 | 2.69–16.04 | 0.011 |
| VT | 16 | 6.94 | 0.81–13.06 | 0.029 | 16 | 2.94 | 0.51–1.76 | 0.258 | 16 | 0.63 | 0.51–1.76 | 0.258 | 16 | 6.94 | 0.81–13.06 | 0.029 | 16 | 2.94 | 0.51–1.76 | 0.258 | 16 | 0.63 | 0.51–1.76 | 0.258 |

Reduction here denotes reduction in the average number of days affected/visits reported before and after ablation.

### Discussion

#### Findings

The findings of the study are encouraging, and the high response rate suggests that collection of PROMs in this patient group is feasible. The improvement in symptom occurrence and severity, reduction in the impact on work and social activities, and reduction in the number of GP/hospital visits indicate that the procedure has a considerable positive impact on the quality of life for the majority of patients. As well as the impact of symptoms on patients’ functional abilities, the pre-ablation responses illustrate the wider implications regarding service use and work days lost. In general, the results of the newly developed tools showed high correlation with the EQ5D. However, the newly developed tools showed increased sensitivity to issues such as changes in patient symptoms and concerns, and provided useful data to compare between arrhythmia substrates. It was also able to identify complications and assess patient expectation.

#### Study limitations

As pre- and post-procedure questionnaires were sent out together, the volume of questionnaires may have deterred some responders. However, as the primary aim was to test acceptability and understanding of the questionnaires and the feasibility of gaining responses, this limitation was felt to be acceptable. Furthermore, as this study was not conducted in real time, some patients were completing the questionnaires up to 16 months post-procedure. This led to reliance on patient memory, and some struggled to recall how they felt prior to the procedure. Moreover, the study was conducted in real time, some patients may have been completing the questionnaires up to 16 months post-procedure. This led to reliance on patient memory, and some struggled to recall how they felt prior to the procedure, while others may have given inaccurate answers, potentially biased by treatment outcomes for example, leading to erroneous data. Some patients received additional treatment during the time period or may have suffered from other health problems making it difficult to differentiate between arrhythmia-associated complications and non-related symptoms. In some cases, patients stated that they experienced an initial improvement in symptoms following the ablation, followed by a subsequent deterioration. This may have been due to a natural disease progression which would not have been picked up by the process if it had been administered in a manner which did not take into account the patient’s overall health status.
traditional way. As with any PROMs it can be argued that the non-
responders may be those who benefitted least (or most) from the
procedure, again leading to skewed data.

**Weakness of the tools**
The weaknesses highlighted in the audit can largely be rectified by
simple rewording of affected questions; however, some areas
require more extensive work to clarify issues. This is the case in
areas including how to address “normal routine” in patients who
are retired or do not work, and how to encourage patients to com-
plete all fields even when they feel a question does not apply to them.

Additional areas to consider for improving the questionnaire
include the insertion of questions relating to medications used to
identify changes in these following the procedure, and also informa-
tion regarding co-morbidities. This will add depth of understanding to
the questionnaires; particularly to the EQSD which may show little
change following a highly successful ablation procedure if a patient
has unrelated medical problems. Using feedback from patients as
part of an iterative process of questionnaire improvement is an im-
portant stage in the validation process.

**Strengths of the study**
The audit received a satisfactory response rate, suggesting that the
length and content of the questionnaires were not unreasonable,
even in the format used where both pre-and post-procedure ques-
tionnaires were received together. Feedback received from patients
during telephone enquiries and via comments on the questionnaires
was useful and gave an insight into areas requiring clarification: a
useful mechanism to improve the tools. Patients were pleased to
have the opportunity to comment on the treatment they had
received.

High success rates for catheter ablation have been reported in the
literature, with up to 99% success in some studies. The feedback
received from patients in this study also suggests that ablation
affords a high level of patient satisfaction, while giving data in a
greater depth of detail. Overall, the results showed that cardiac abla-
tion leads to a significant improvement in symptoms in the majority of
patients; this supports its use as a technique for improving the quality
of life in patients suffering from cardiac arrhythmias. Improvements
seen in the EQ-5D VAS and Index scores (75.1 and 70.3% of patients
reported an improvement, respectively) compare well with those
observed in the National PROMs programme (during 2009–2010,
groin, hernia, hip replacement, knee replacement, and varicose vein
surgery saw VAS improvements of 39.1, 61.4, 50.8, and 39.8%, re-
spectively, with index score improvements in 50.5, 86.7, 77.9, and
51.6%, respectively).

**Conclusion**
This pilot study has provided a solid foundation on which to build a
robust disease-specific PROM tool for cardiac ablation. The process
was successful with high response and completion rates, sup-
porting the feasibility of collecting PROMs in this patient group. Al-
though this audit was only a preliminary part of the PROMs
development procedure, the responses are a useful part of the valid-
atation process and facilitate improvements to the tools and method
involved. The results of responses during these preliminary stages
are very encouraging and illustrate the benefits of performing car-
diac ablation in symptomatic patients. Further research is aimed
at psychometric testing and validation of the tool. Cardiac arrhyth-
mias have an adverse effect on the quality of life of many patients
and successful treatment can be life-enhancing.

**Further research**
Following the success of this audit, further work into this area has
been commissioned by the National Institute of Health and Care
Excellence. Based on the responses received, the questionnaires
have been updated and adapted into single pre- and post-procedure
documents. Ethical approval has been given and a two-phase study is
now underway (registered on the Clinical Trials website, reference:
NCT01672528). This comprises of patient interviews to test, im-
prove, and retest the questionnaires further and a postal survey
phase involving up to 600 patients from three study centres as part
of a prospective study. These patients will receive questionnaire pre-
ablation, at 8–16 weeks, post-procedure and at 1 and 5 years post-
procedure. The aim of this further study is to produce a validated
PROMs tool for use in the UK to collect data from ablation patients.
This will facilitate national measurement of the health change in
patients following ablation therapy, and will allow statistical compari-
son between arrhythmia substrates and other subgroups.

**Acknowledgements**
The authors thank Dr Mark Kelly (South East Wales Trials Unit,
Cardiff University, Wales) for statistical support.

**Conflict of interest:** S.M. acts as an advisor to two companies
which manufacture cardiac ablation equipment: Medtronic and
Boston Scientific.

**Funding**
Cedar is funded by the National Institute of Health and Care Excellence
(NICE) to act as an External Assessment Centre (EAC) for the Medical
Technologies Evaluation Programme. Funding to pay the Open Access
publication charges for this article was provided by Cedar.

**References**
www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/
dh_117794.pdf (26 September 2013, accessed).
4. Black N. Patient reported outcome measures could help transform healthcare. BMJ
2013;346:f167.
5. Roehr B. Potential benefits of “well engaged patients” a rekindle to those from a block-
6. Devlin N, Appleby J. Getting the Most Out of PROMs: Putting Health Outcomes at the
management of atrial fibrillation: the Task Force for the Management of Atrial Fibril-
9. Wood KA, Wiener CL, Kayser-Jones J. Supraventricular tachycardia and the struggle
Peritricuspid reentrant ventricular tachycardia in Ebstein’s anomaly

Senthil Kumar¹, Anandaraja Subramanian², and Raja J. Selvaraj¹*

¹Department of Cardiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry 605007, India and ²Indira Gandhi Government General Hospital and Postgraduate Institute, Puducherry, India

* Corresponding author. Tel: +91 9442242648; fax: +91 413 2272067, E-mail address: raja.selvaraj@jipmer.edu.in

A 40-year-old woman with Ebstein’s anomaly of the tricuspid valve presented with recurrent palpitations. Electrocardiogram during the episode showed a regular broad complex tachycardia at 150 beats per minute with left bundle branch abnormality morphology, left axis deviation and dissociated, slower atrial activity.

During electrophysiology study, tachycardia was induced by double ventricular extrastimuli. Mapping of the right ventricle was performed during tachycardia using an electroanatomical three-dimensional mapping system (CARTO, Biosense Webster). Bipolar voltage map showed a large scar in the basal inferior right ventricle. Figure shows the activation map in a modified posterior view, with activation proceeding around the tricuspid annulus and a ‘head meets tail’ pattern. Radiofrequency ablation was done to interrupt the isthmus between the scar and the annulus. Tachycardia was no longer inducible after the ablation.

Ventricular tachycardia is rare in Ebstein’s anomaly. In our patient, scarring in the inferior, atrialized portion of the right ventricle formed a substrate for peritricuspid reentry. Reentry around the tricuspid annulus has been previously described in patients with arrhythmogenic right ventricular dysplasia, but not, to our knowledge, in Ebstein’s anomaly.

The full-length version of this report can be viewed at: http://www.escardio.org/communities/EHRA/publications/ep-case-reports/Documents/Peritricuspid-reentrant-ventricular.pdf.